The effects of the extent of lymph node dissection during radical prostatectomy on prostate cancer survival outcomes have been unclear, pending long-term follow-up data from randomized controlled ...

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

The GPS Mdx test is a 17-gene expression assay performed on prostate biopsy tissue that may identify signals of favorable vs unfavorable pathology.

BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS) in patients with prostate cancer at high risk for biochemical recurrence, ...

The postsurgical combination of androgen deprivation therapy and Erleada has shown promising results in prostate cancer. Postsurgical treatment with androgen deprivation therapy and Erleada ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a ...

Urologic surgeon Jose M. Flores, MD is lead author of a new study investigating the risk of biochemical recurrence after radical prostatectomy when taking ED drugs. There have been conflicting studies ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.